Ligand Pharmaceuticals (LGND) – Investment Analysts’ Recent Ratings Changes

Ligand Pharmaceuticals (NASDAQ: LGND) has recently received a number of price target changes and ratings updates:

  • 11/5/2018 – Ligand Pharmaceuticals was given a new $281.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.
  • 10/29/2018 – Ligand Pharmaceuticals was given a new $280.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.
  • 10/29/2018 – Ligand Pharmaceuticals was upgraded by analysts at Roth Capital from a “neutral” rating to a “buy” rating. They now have a $195.00 price target on the stock, down previously from $250.00.
  • 10/27/2018 – Ligand Pharmaceuticals was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 10/19/2018 – Ligand Pharmaceuticals was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 10/18/2018 – Ligand Pharmaceuticals was given a new $280.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.
  • 10/12/2018 – Ligand Pharmaceuticals was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 10/11/2018 – Ligand Pharmaceuticals was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating.
  • 10/4/2018 – Ligand Pharmaceuticals was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating.
  • 10/2/2018 – Ligand Pharmaceuticals had its price target raised by analysts at HC Wainwright from $270.00 to $280.00. They now have a “buy” rating on the stock.
  • 9/19/2018 – Ligand Pharmaceuticals was given a new $270.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.
  • 9/11/2018 – Ligand Pharmaceuticals was given a new $300.00 price target on by analysts at Argus. They now have a “buy” rating on the stock. They noted that the move was a valuation call. They noted that the move was a valuation call.

Shares of NASDAQ LGND traded down $6.39 during trading hours on Monday, reaching $159.33. 957,614 shares of the stock were exchanged, compared to its average volume of 402,743. The firm has a market cap of $3.50 billion, a P/E ratio of 62.00, a price-to-earnings-growth ratio of 1.45 and a beta of 1.52. The company has a current ratio of 2.34, a quick ratio of 2.32 and a debt-to-equity ratio of 0.96. Ligand Pharmaceuticals Inc. has a 52 week low of $126.50 and a 52 week high of $278.62.

Ligand Pharmaceuticals (NASDAQ:LGND) last posted its quarterly earnings data on Monday, August 6th. The biotechnology company reported $2.59 EPS for the quarter, topping the Zacks’ consensus estimate of $2.34 by $0.25. Ligand Pharmaceuticals had a return on equity of 25.95% and a net margin of 52.10%. The firm had revenue of $90.00 million for the quarter, compared to analyst estimates of $82.20 million. During the same quarter last year, the company earned $0.67 EPS. The company’s revenue was up 221.4% on a year-over-year basis. Analysts forecast that Ligand Pharmaceuticals Inc. will post 5.71 EPS for the current year.

In other Ligand Pharmaceuticals news, SVP Charles S. Berkman sold 19,417 shares of the firm’s stock in a transaction on Tuesday, September 4th. The stock was sold at an average price of $254.99, for a total transaction of $4,951,140.83. Following the transaction, the senior vice president now owns 28,232 shares in the company, valued at approximately $7,198,877.68. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director John W. Kozarich sold 2,500 shares of the firm’s stock in a transaction on Monday, October 1st. The stock was sold at an average price of $275.04, for a total value of $687,600.00. Following the transaction, the director now owns 26,142 shares in the company, valued at approximately $7,190,095.68. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 119,922 shares of company stock worth $30,297,452. Corporate insiders own 7.80% of the company’s stock.

A number of institutional investors have recently bought and sold shares of the business. Dupont Capital Management Corp increased its stake in Ligand Pharmaceuticals by 39.5% during the 3rd quarter. Dupont Capital Management Corp now owns 16,680 shares of the biotechnology company’s stock worth $4,578,000 after acquiring an additional 4,721 shares during the period. Penserra Capital Management LLC increased its stake in Ligand Pharmaceuticals by 4.0% during the 3rd quarter. Penserra Capital Management LLC now owns 73,513 shares of the biotechnology company’s stock worth $20,177,000 after acquiring an additional 2,821 shares during the period. Lisanti Capital Growth LLC increased its stake in Ligand Pharmaceuticals by 13.8% during the 3rd quarter. Lisanti Capital Growth LLC now owns 16,280 shares of the biotechnology company’s stock worth $4,469,000 after acquiring an additional 1,975 shares during the period. Los Angeles Capital Management & Equity Research Inc. increased its stake in Ligand Pharmaceuticals by 65.8% during the 3rd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 4,811 shares of the biotechnology company’s stock worth $1,321,000 after acquiring an additional 1,910 shares during the period. Finally, American Century Companies Inc. increased its stake in Ligand Pharmaceuticals by 7.6% during the 3rd quarter. American Century Companies Inc. now owns 26,449 shares of the biotechnology company’s stock worth $7,260,000 after acquiring an additional 1,869 shares during the period.

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; Baxdela, a captisol-enabled delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections; Nexterone, a captisol-enabled formulation of amiodarone; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Carnexiv, which is indicated as replacement therapy for oral carbamazepine formulations; bazedoxifene for the treatment of postmenopausal osteoporosis; commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta for non-small cell lung cancer.

Featured Story: NASDAQ Stock Market Explained

Receive News & Ratings for Ligand Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply